XML 44 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Segment Reporting (Tables)

9 Months Ended

Aug. 31, 2019

Segment Reporting [Abstract]

Summary of Net Revenue, Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment

The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, interest expense, and income tax (expense) benefit for the three months and nine months ended August 31, 2019 and August 31, 2018:

		For the three months ended August 31, 2019				For the three months ended August 31, 2018
Net revenue
Umbilical cord blood and cord tissue stem cell service		$	8,029,797			$	7,776,339
Prepacyte®-CB			33,035				29,308
Public cord blood banking			160,561				65,575
Total net revenue		$	8,223,393			$	7,871,222
Cost of sales
Umbilical cord blood and cord tissue stem cell service		$	2,240,257			$	2,149,778
Prepacyte®-CB			25,180				27,740
Public cord blood banking			323,898				308,662
Total cost of sales		$	2,589,335			$	2,486,180
Depreciation and amortization
Umbilical cord blood and cord tissue stem cell service		$	38,223			$	43,008
Prepacyte®-CB			9,063				9,064
Public cord blood banking			—				—
Total depreciation and amortization		$	47,286			$	52,072
Operating (loss) income
Umbilical cord blood and cord tissue stem cell service		$	2,175,563			$	1,170,704
Prepacyte®-CB			(19,146	)			( 7,496	)
Public cord blood banking			(163,336	)			(243,086	)
Total operating income		$	1,993,081			$	920,122
Interest expense
Umbilical cord blood and cord tissue stem cell service		$	413,942			$	410,366
Prepacyte®-CB			—				—
Public cord blood banking			—				—
Total interest expense		$	413,942			$	410,366
Income tax expense
Umbilical cord blood and cord tissue stem cell service		$	498,748			$	303,072
Prepacyte®-CB			—				—
Public cord blood banking			—				—
Total income tax expense		$	498,748			$	303,072

		For the nine months ended August 31, 2019				For the nine months ended August 31, 2018
Net revenue
Umbilical cord blood and cord tissue stem cell service		$	23,246,521			$	20,475,020
Prepacyte®-CB			70,795				84,208
Public cord blood banking			529,041				65,575
Total net revenue		$	23,846,357			$	20,624,803
Cost of sales
Umbilical cord blood and cord tissue stem cell service		$	6,497,788			$	5,431,359
Prepacyte®-CB			189,806				124,805
Public cord blood banking			996,259				308,662
Total cost of sales		$	7,683,853			$	5,864,826
Depreciation and amortization
Umbilical cord blood and cord tissue stem cell service		$	132,409			$	97,674
Prepacyte®-CB			27,191				27,191
Public cord blood banking			—				—
Total depreciation and amortization		$	159,600			$	124,865
Operating (loss) income
Umbilical cord blood and cord tissue stem cell service		$	6,307,426			$	3,521,625
Prepacyte®-CB			(164,141	)			(67,788	)
Public cord blood banking			(2,799,978	)			(243,087	)
Total operating income		$	3,343,307			$	3,056,995
Interest expense
Umbilical cord blood and cord tissue stem cell service		$	1,245,154			$	995,437
Prepacyte®-CB			—				—
Public cord blood banking			—				—
Total interest expense		$	1,245,154			$	995,437
Income tax expense
Umbilical cord blood and cord tissue stem cell service		$	654,358			$	3,821,660
Prepacyte®-CB			—				—
Public cord blood banking			—				—
Total income tax expense		$	654,358			$	3,821,660

The following table shows the assets by segment as of August 31, 2019 and November 30, 2018:

		As of August 31, 2019				As of November 30, 2018
Assets
Umbilical cord blood and cord tissue stem cell service		$	28,132,949			$	26,239,260
Prepacyte®-CB			202,408				319,802
Public cord blood banking			13,492,399				15,831,081
Total assets		$	41,827,756			$	42,390,143

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration